NO2560611T3 - - Google Patents

Info

Publication number
NO2560611T3
NO2560611T3 NO11719211A NO11719211A NO2560611T3 NO 2560611 T3 NO2560611 T3 NO 2560611T3 NO 11719211 A NO11719211 A NO 11719211A NO 11719211 A NO11719211 A NO 11719211A NO 2560611 T3 NO2560611 T3 NO 2560611T3
Authority
NO
Norway
Application number
NO11719211A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42710544&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2560611(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of NO2560611T3 publication Critical patent/NO2560611T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO11719211A 2010-04-21 2011-04-19 NO2560611T3 (et)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10160565 2010-04-21
EP11719211.2A EP2560611B1 (en) 2010-04-21 2011-04-19 "process for providing particles with reduced electrostatic charges"
PCT/EP2011/056227 WO2011131663A1 (en) 2010-04-21 2011-04-19 "process for providing particles with reduced electrostatic charges"

Publications (1)

Publication Number Publication Date
NO2560611T3 true NO2560611T3 (et) 2018-06-02

Family

ID=42710544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO11719211A NO2560611T3 (et) 2010-04-21 2011-04-19

Country Status (26)

Country Link
US (3) US20110262543A1 (et)
EP (1) EP2560611B1 (et)
JP (1) JP5913289B2 (et)
KR (2) KR20130062268A (et)
CN (1) CN102858320B (et)
AR (1) AR081540A1 (et)
AU (1) AU2011244384B2 (et)
BR (1) BR112012026804B1 (et)
CA (1) CA2796934C (et)
DK (1) DK2560611T3 (et)
ES (1) ES2658179T3 (et)
HK (1) HK1174570A1 (et)
HR (1) HRP20180488T1 (et)
HU (1) HUE038555T2 (et)
IL (1) IL222519B (et)
MX (1) MX2012012045A (et)
MY (1) MY163011A (et)
NO (1) NO2560611T3 (et)
PL (1) PL2560611T3 (et)
PT (1) PT2560611T (et)
RU (1) RU2580312C2 (et)
SG (1) SG184964A1 (et)
SI (1) SI2560611T1 (et)
TW (1) TWI530301B (et)
UA (1) UA111470C2 (et)
WO (1) WO2011131663A1 (et)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013009525A (es) * 2011-02-17 2013-10-01 Cipla Ltd Combinacion de glicopirrolato y un beta2-agonista.
DE102011102614A1 (de) * 2011-05-27 2012-11-29 Roland Nied Verfahren zum Betrieb einer Strahlmühle sowie Strahlmühle
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
EP2804583A1 (en) * 2012-01-16 2014-11-26 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
WO2013109209A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising fluticasone
RS63706B1 (sr) 2012-01-25 2022-11-30 Chiesi Farm Spa Formulacija suvog praha koja sadrži kortikosteroid i beta-adrenergik, za primenu inhalacijom
GB201205632D0 (en) * 2012-03-30 2012-05-16 Vectura Ltd Method and apparatus
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
WO2014106727A1 (en) * 2013-01-03 2014-07-10 Vectura Limited Inhaler and formulation
PL3019153T3 (pl) * 2013-07-11 2019-02-28 Chiesi Farmaceutici S.P.A. Preparat proszkowy zawierający środek antycholinergiczny, kortykosteroid i środek beta-adrenergiczny do podawania wziewnego
US9427376B2 (en) * 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
GB201408387D0 (en) * 2014-05-12 2014-06-25 Teva Pharmaceuticals Europ B V Treatment of respiratory disorders
US9554992B2 (en) * 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
LT3191081T (lt) 2014-09-09 2020-07-10 Vectura Limited Vaisto forma, apimanti glikopiroliatą, būdas ir aparatūra
HUE056402T2 (hu) 2015-11-16 2022-02-28 Chiesi Farm Spa Eljárás antikolinerg szert, kortikoszteroidot és béta-adrenerg szert tartalmazó száraz porkészítmény elõállítására
CN105891616B (zh) * 2016-06-15 2018-06-15 北京航空航天大学 一种研究带电颗粒与火焰相互作用的实验装置
WO2018018669A1 (en) * 2016-07-28 2018-02-01 Esd Technology Consulting & Licensing Co., Ltd. Static charge reduction system
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
US11774363B2 (en) * 2018-08-07 2023-10-03 Norton (Waterford) Limited Application of raman spectroscopy for the manufacture of inhalation powders
EP4034079A1 (en) 2019-09-24 2022-08-03 Chiesi Farmaceutici S.p.A. Novel carrier particles for dry powder formulations for inhalation
CN116194087A (zh) * 2020-01-15 2023-05-30 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CA3189493A1 (en) 2020-08-14 2022-02-17 Brian Paul O'NEILL An inhalable formulation of fluticasone propionate and albuterol sulfate
CN116077471A (zh) * 2021-11-08 2023-05-09 上海臣邦医药科技股份有限公司 一种供吸入用的粉雾剂组合物及其制备方法和应用
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂
CN115400103B (zh) * 2022-09-22 2023-11-24 苏州易合医药有限公司 一种多孔性呼吸颗粒及其制备方法
WO2024062007A1 (en) 2022-09-22 2024-03-28 Chiesi Farmaceutici S.P.A. Capsule inhaler for the administration of a phosphodiesterase-4 inhibitor

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5A (en) * 1836-08-10 Thomas blancharjq
IT1204826B (it) * 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5875776A (en) * 1996-04-09 1999-03-02 Vivorx Pharmaceuticals, Inc. Dry powder inhaler
EP2036544B1 (en) * 1997-03-20 2016-12-28 Merck Sharp & Dohme Corp. Dosage form of powder agglomerates
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
AU6926101A (en) * 2000-06-27 2002-01-08 Vectura Ltd Method of making particles for use in a pharmaceutical composition
GB0030074D0 (en) * 2000-12-08 2001-01-24 Univ London Pharmacy Particulate inhalation carrier
PT1658872E (pt) 2002-07-31 2011-05-12 Chiesi Farma Spa Inalador de p?
EP1643973A1 (en) * 2003-07-11 2006-04-12 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
RU2006141358A (ru) * 2004-04-23 2008-05-27 Сайдекс, Инк. (Us) Препаративная форма для ингалятора сухого порошка, содержащая простой сульфоалкиловый эфир циклодекстрина
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
DE102006030166A1 (de) * 2006-06-29 2008-01-10 Boehringer Ingelheim Pharma Gmbh & Co. Kg Tempern
WO2008006509A1 (en) 2006-07-14 2008-01-17 Chiesi Farmaceutici S.P.A. Derivatives of 1-phenyl-2-pyridynyl alkylene alcohols as phosphodiesterase inhibitors
EP2022783A1 (en) 2007-08-08 2009-02-11 CHIESI FARMACEUTICI S.p.A. "Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors"
EP2154136A1 (en) 2008-08-08 2010-02-17 CHIESI FARMACEUTICI S.p.A. Quinuclidine carbonate derivatives and medicinal compositions thereof

Also Published As

Publication number Publication date
KR101863523B1 (ko) 2018-05-31
MX2012012045A (es) 2012-12-17
IL222519B (en) 2018-03-29
HUE038555T2 (hu) 2018-10-29
AR081540A1 (es) 2012-10-03
AU2011244384B2 (en) 2016-06-23
SG184964A1 (en) 2012-11-29
HK1174570A1 (en) 2013-06-14
MY163011A (en) 2017-07-31
SI2560611T1 (en) 2018-03-30
PL2560611T3 (pl) 2018-05-30
JP2013525327A (ja) 2013-06-20
WO2011131663A1 (en) 2011-10-27
CA2796934C (en) 2018-11-20
US20190216731A1 (en) 2019-07-18
BR112012026804A2 (pt) 2016-07-12
KR20170118975A (ko) 2017-10-25
IL222519A0 (en) 2012-12-31
AU2011244384A1 (en) 2012-11-15
EP2560611A1 (en) 2013-02-27
TW201206498A (en) 2012-02-16
TWI530301B (zh) 2016-04-21
US20110262543A1 (en) 2011-10-27
CN102858320A (zh) 2013-01-02
CA2796934A1 (en) 2011-10-27
DK2560611T3 (en) 2018-02-26
JP5913289B2 (ja) 2016-04-27
CN102858320B (zh) 2014-10-29
BR112012026804B1 (pt) 2021-11-16
UA111470C2 (uk) 2016-05-10
PT2560611T (pt) 2018-02-07
RU2012145762A (ru) 2014-05-27
EP2560611B1 (en) 2018-01-03
US20230364015A1 (en) 2023-11-16
ES2658179T3 (es) 2018-03-08
RU2580312C2 (ru) 2016-04-10
KR20130062268A (ko) 2013-06-12
HRP20180488T1 (hr) 2018-07-13

Similar Documents

Publication Publication Date Title
BR112013008959A2 (et)
BR112012031500A2 (et)
BR112012029986A2 (et)
BR112012030039A2 (et)
BR112012028408A2 (et)
BR112012026492A2 (et)
BR112012027808A2 (et)
BR112012024897A2 (et)
BR112012025307A2 (et)
BR112012019354A2 (et)
BR112012002126A2 (et)
BR112012026946A2 (et)
BR112012017960A2 (et)
BR112012025482A2 (et)
BR112012031826A2 (et)
BR112012028186A2 (et)
BR112012023249A2 (et)
NO2560611T3 (et)
BR112012016456A2 (et)
BR112012018256A2 (et)
BR112012027015A2 (et)
BR112012025308A2 (et)
BR112012027945A2 (et)
BR112012024872A2 (et)
BR112012023265A2 (et)